MA43131B1 - Compositions et procédés d'inhibition de l'activité de l'arginase - Google Patents

Compositions et procédés d'inhibition de l'activité de l'arginase

Info

Publication number
MA43131B1
MA43131B1 MA43131A MA43131A MA43131B1 MA 43131 B1 MA43131 B1 MA 43131B1 MA 43131 A MA43131 A MA 43131A MA 43131 A MA43131 A MA 43131A MA 43131 B1 MA43131 B1 MA 43131B1
Authority
MA
Morocco
Prior art keywords
methods
compositions
arginase activity
inhibiting arginase
compounds
Prior art date
Application number
MA43131A
Other languages
English (en)
Inventor
Eric Sjogren
Jim Li
Zandt Michael Van
Darren Whitehouse
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of MA43131B1 publication Critical patent/MA43131B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne une nouvelle classe de composés qui présentent une activité inhibitrice par rapport à l'arginase, et des compositions pharmaceutiques comprenant les composés de l'invention. L'invention concerne également des méthodes de traitement du cancer à l'aide des inhibiteurs d'arginase selon l'invention.
MA43131A 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase MA43131B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15
PCT/US2016/059342 WO2017075363A1 (fr) 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase

Publications (1)

Publication Number Publication Date
MA43131B1 true MA43131B1 (fr) 2020-07-29

Family

ID=58631120

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43131A MA43131B1 (fr) 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase
MA050636A MA50636A (fr) 2015-10-30 2016-10-28 Compositions et procédés pour inhiber l'activité d'arginase

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA050636A MA50636A (fr) 2015-10-30 2016-10-28 Compositions et procédés pour inhiber l'activité d'arginase

Country Status (36)

Country Link
US (4) US10065974B2 (fr)
EP (3) EP4011887B1 (fr)
JP (3) JP6833844B2 (fr)
KR (2) KR20220118559A (fr)
CN (4) CN113201002A (fr)
AU (3) AU2016343656B2 (fr)
BR (3) BR122020022280B1 (fr)
CA (1) CA3003271A1 (fr)
CL (4) CL2018001134A1 (fr)
CO (1) CO2018004750A2 (fr)
CR (3) CR20180282A (fr)
CY (1) CY1123557T1 (fr)
DK (1) DK3368541T3 (fr)
EA (1) EA038276B1 (fr)
EC (1) ECSP18040250A (fr)
ES (2) ES2808988T3 (fr)
HK (1) HK1252560A1 (fr)
HR (1) HRP20201046T1 (fr)
HU (1) HUE054972T2 (fr)
IL (3) IL258731B (fr)
LT (1) LT3368541T (fr)
MA (2) MA43131B1 (fr)
MD (1) MD3368541T2 (fr)
MX (1) MX2018005294A (fr)
MY (1) MY201783A (fr)
NZ (1) NZ742742A (fr)
PH (1) PH12018500899A1 (fr)
PL (1) PL3368541T3 (fr)
PT (1) PT3368541T (fr)
RS (1) RS60695B1 (fr)
SG (4) SG10202003966RA (fr)
SI (1) SI3368541T1 (fr)
TW (3) TWI775556B (fr)
UA (1) UA125289C2 (fr)
WO (1) WO2017075363A1 (fr)
ZA (4) ZA201803556B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2586219C2 (ru) 2010-04-22 2016-06-10 Марс, Инкорпорейтед Ингибиторы аргиназы и их терапевтические применения
EP3719024A1 (fr) 2010-10-26 2020-10-07 Mars, Incorporated Inhibiteurs d'arginase en tant qu'agents thérapeutiques
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3538111B1 (fr) * 2016-11-08 2022-01-19 Calithera Biosciences, Inc. Polythérapies faisant appel à un inhibiteur d'arginase
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
WO2018209290A1 (fr) * 2017-05-12 2018-11-15 Calithera Biosciences, Inc. Procédé de préparation de (3r,4s)-3-acétamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
MX2020008570A (es) 2018-02-17 2020-09-21 Astrazeneca Ab Inhibidores de arginasa y sus metodos de uso.
US12054500B2 (en) 2018-03-05 2024-08-06 Arcus Biosciences, Inc. Arginase inhibitors
WO2019177873A1 (fr) * 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Inhibiteurs d'arginase et procédés d'utilisation
WO2019186497A1 (fr) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dérivés de pipéridine dipeptidiques
WO2019245890A1 (fr) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Inhibiteurs d'arginase et procédés d'utilisation
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
EP3917936A4 (fr) * 2019-02-06 2022-12-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Acides alkylboroniques en tant qu'inhibiteurs d'arginase
CN113727975A (zh) * 2019-05-02 2021-11-30 阿克拉瑞斯治疗股份有限公司 作为jak抑制剂的被取代的吡咯并吡啶
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
WO2021141751A1 (fr) * 2020-01-07 2021-07-15 Merck Sharp & Dohme Corp. Inhibiteurs d'arginase et méthodes d'utilisation
WO2021257857A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
JP2023533724A (ja) 2020-07-02 2023-08-04 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
TW202216662A (zh) * 2020-07-17 2022-05-01 美商英塞特公司 製備精胺酸酶抑制劑及其合成中間物之方法
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
EP4298099A1 (fr) 2021-02-25 2024-01-03 Incyte Corporation Lactames spirocycliques utilisés comme inhibiteurs du v617f de jak2
US20230295124A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
PT999825E (pt) 1997-07-29 2004-02-27 Alcon Lab Inc Composicoes oftalmicas contendo polimeros de galactomanano e borato
CA2305703A1 (fr) 1997-10-10 1999-04-22 David W. Christianson Compositions et procedes pour inhiber l'activite de l'arginase
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6720188B2 (en) 2000-07-06 2004-04-13 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (fr) 2003-06-02 2004-12-02 Catherine Adele O'brien Amelioration de l'immunite contre le cancer par l'intermediaire de l'inhibition de l'arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP2113246B1 (fr) 2003-08-07 2016-06-22 Allergan, Inc. Compositions d'administration d'agents therapeutiques dans les yeux et leurs methodes d'elaboration et d'utilisation
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20090298912A1 (en) 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
JP5386353B2 (ja) 2007-07-12 2014-01-15 山洋電気株式会社 二重反転式軸流送風機
EP2214660A2 (fr) * 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Acides gras de type oméga-3, acides gras polyinsaturés hydroxylés, composés de lipoxine ou composés d'oxylipine pour le traitement de maladies ophtalmiques
CA2722992A1 (fr) * 2008-05-05 2009-11-12 Schering Corporation Administration sequentielle d'agents de chimiotherapie pour le traitement du cancer
LT2389352T (lt) 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
RU2586219C2 (ru) 2010-04-22 2016-06-10 Марс, Инкорпорейтед Ингибиторы аргиназы и их терапевтические применения
EP3719024A1 (fr) * 2010-10-26 2020-10-07 Mars, Incorporated Inhibiteurs d'arginase en tant qu'agents thérapeutiques
CN110123820B (zh) 2010-12-31 2022-05-31 阿斯利康公司 精氨酸酶抑制剂及其使用方法
CN104244932B (zh) 2011-10-19 2017-02-22 马尔斯公司 精氨酸酶抑制剂和其治疗应用
CN104394869A (zh) 2011-10-20 2015-03-04 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
JP6152167B2 (ja) * 2012-04-18 2017-06-21 マーズ インコーポレイテッド アルギナーゼ阻害剤としての環拘束性類似体
PE20151604A1 (es) * 2012-11-02 2015-11-04 Pharmacyclics Llc Terapia adyuvante con inhibidores de quinasa de la familia tec
CN105848680A (zh) * 2013-10-25 2016-08-10 药品循环有限责任公司 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 ***的增效药物复合物及其制备方法
EP3270907A1 (fr) 2015-03-20 2018-01-24 Sammy Oyoo OPIYO Utilisation de suramine et d'inhibiteurs de l'arginase dans une néoplasie maligne
CN107921051A (zh) 2015-06-23 2018-04-17 卡里塞拉生物科学股份公司 抑制精氨酸酶活性的组合物和方法
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
JP2018533582A (ja) 2018-11-15
SG11201802961PA (en) 2018-05-30
US10851118B2 (en) 2020-12-01
TW202110858A (zh) 2021-03-16
TWI734630B (zh) 2021-07-21
WO2017075363A1 (fr) 2017-05-04
CL2019000819A1 (es) 2019-08-09
IL281503B (en) 2022-01-01
PH12018500899A1 (en) 2018-10-29
LT3368541T (lt) 2020-09-25
TWI710565B (zh) 2020-11-21
IL258731B (en) 2021-04-29
KR20220118559A (ko) 2022-08-25
CN113150016A (zh) 2021-07-23
CL2019000821A1 (es) 2019-08-09
BR122020022280B1 (pt) 2022-05-03
JP2021075543A (ja) 2021-05-20
CL2019000820A1 (es) 2019-08-09
EP4011887A1 (fr) 2022-06-15
EP3693375B1 (fr) 2022-02-16
EA038276B1 (ru) 2021-08-04
AU2020286278A1 (en) 2021-01-14
HK1252560A1 (zh) 2019-05-31
MY201783A (en) 2024-03-18
TWI775556B (zh) 2022-08-21
BR112018008746A2 (pt) 2018-10-30
CN108271371A (zh) 2018-07-10
US10844080B2 (en) 2020-11-24
CR20210390A (es) 2021-10-19
ECSP18040250A (es) 2018-10-31
MD3368541T2 (ro) 2020-09-30
CR20210389A (es) 2021-09-16
IL281503A (en) 2021-04-29
BR112018008746B1 (pt) 2021-11-16
CY1123557T1 (el) 2022-03-24
KR102434308B1 (ko) 2022-08-19
CN113150015A (zh) 2021-07-23
RS60695B1 (sr) 2020-09-30
JP6833844B2 (ja) 2021-02-24
BR122020022275B1 (pt) 2022-05-03
EP3368541A1 (fr) 2018-09-05
ES2808988T3 (es) 2021-03-02
CN108271371B (zh) 2021-02-09
AU2016343656A1 (en) 2018-06-07
BR112018008746A8 (pt) 2019-02-26
ZA201907093B (en) 2021-03-31
CL2018001134A1 (es) 2018-10-26
SG10201911406TA (en) 2020-01-30
MX2018005294A (es) 2018-09-21
EP3368541A4 (fr) 2019-07-17
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
JP2022071010A (ja) 2022-05-13
HRP20201046T1 (hr) 2020-10-16
ZA201803556B (en) 2021-02-24
SI3368541T1 (sl) 2020-10-30
MA50636A (fr) 2021-04-14
CA3003271A1 (fr) 2017-05-04
HUE054972T2 (hu) 2021-10-28
TW201726692A (zh) 2017-08-01
EP3693375A1 (fr) 2020-08-12
IL258731A (en) 2018-06-28
PT3368541T (pt) 2020-07-06
UA125289C2 (uk) 2022-02-16
SG10201911402YA (en) 2020-02-27
JP7032583B2 (ja) 2022-03-08
AU2022203703A1 (en) 2022-06-16
IL288225A (en) 2022-01-01
ZA201907092B (en) 2021-04-28
KR20180084063A (ko) 2018-07-24
TW202146028A (zh) 2021-12-16
US20200223872A1 (en) 2020-07-16
US20180346489A1 (en) 2018-12-06
CN113201002A (zh) 2021-08-03
ZA201907091B (en) 2021-05-26
US10065974B2 (en) 2018-09-04
AU2016343656B2 (en) 2020-09-17
PL3368541T3 (pl) 2020-11-02
AU2020286278B2 (en) 2022-03-17
DK3368541T3 (da) 2020-06-29
CO2018004750A2 (es) 2018-10-31
EA201891057A1 (ru) 2018-12-28
ES2910928T3 (es) 2022-05-17
EP3368541B1 (fr) 2020-05-27
US20210061822A1 (en) 2021-03-04
US20170121352A1 (en) 2017-05-04
EP4011887B1 (fr) 2024-07-31
CR20180282A (es) 2018-11-30

Similar Documents

Publication Publication Date Title
MA43131B1 (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
PH12017500629A1 (en) Immuniregulatory agents
PH12015502028A1 (en) Ido inhibitors
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201790998A1 (ru) Иммуннорегуляторные агенты
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
WO2015168466A8 (fr) Inhibiteurs de la déméthylase-1 spécifiques de la lysine
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MX2022002398A (es) Formas cristalinas de un inhibidor de cd73.
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
MA47097B1 (fr) Compositions et procédés pour inhiber l'activité de l'arginase
EA202191138A1 (ru) Композиции и способы для ингибирования активности аргиназы
MX2021007967A (es) Inhibidores de síntesis de leucotrienos.
EA202191495A1 (ru) Композиции и способы ингибирования активности аргиназы
MA42711B1 (fr) Méthodes de traitement d'états pathologiques associés à une activation du complément dépendant de masp-2
MA40413B1 (fr) Dérivés de benzodiazépine cytotoxique
MA42681B1 (fr) Inhibiteurs de l'ezh2
MA41049B1 (fr) Compositions et méthodes d'inhibition de l'expression génique d'hao1 (hydroxyacide oxydase 1 (glycolate oxydase))